There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is
attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc.,
is responsible for overseeing the methodology that supports the quantitative fair value. As an
employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics
and Personal Securities Trading Policy in carrying out his responsibilities. For information
regarding Conflicts of Interests,
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to
peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are
statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat,
fair value, and uncertainty rating.
Click here for more on how to use these ratings.
Carna Biosciences, Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines primarily for the treatment of cancer and inflammatory diseases using own innovative kinase drug discovery platform, QuickScout™.
BMA 3F 1-5-5 Minatojima-Minamimachi
Kobe, 650-0047, Japan